The United States remains a global leader in pharmaceutical and biomedical innovation, with small and medium-sized enterprises (SMEs) playing a critical role in developing advanced therapeutics, diagnostics, medical devices, and biotechnology solutions. Despite producing scientifically validated and globally competitive products, many of these firms struggle to achieve successful international market entry and sustained export growth. This article examines the regulatory market entry crisis facing U.S. pharmaceutical and biomedical SMEs, arguing that export underperformance is driven less by product quality and more by systemic regulatory barriers. Specifically, the paper explores how regulatory complexity, fragmented international approval systems, Harmonized System (HS) classification errors, and limited access to affordable compliance infrastructure constrain global market participation. While large pharmaceutical corporations possess dedicated regulatory affairs teams and extensive compliance resources, SMEs often lack the organizational capacity and financial resources necessary to navigate increasingly complex regulatory environments. The consequences extend beyond individual firms, limiting innovation commercialization, reducing export competitiveness, and weakening the global reach of U.S. biomedical innovation. The article further contends that these challenges represent not only a business concern but also a broader issue of national competitiveness, supply chain resilience, and economic security. To address this gap, the paper proposes the recognition of regulatory market entry strategy as a formal strategic discipline and advocates for scalable compliance solutions capable of improving export readiness among pharmaceutical and biomedical SMEs. Strengthening regulatory capabilities may enhance international market access, accelerate innovation diffusion, and reinforce the long-term competitiveness of the U.S. life sciences sector.
Aneke et al. (Thu,) studied this question.